If the U.S. loses its leadership role in the $2 trillion global biotech industry , will it be a victory by China’s government or a self-inflicted American defeat?

Vance Ginn is adamant that it will be the latter, which is why he’s urging the Trump administration to abandon its restrictive tariff and regulatory approach and embrace what made America great in biotech: the free market.

The current debate in Washington, D.C., is between supporters of price controls to lower prescription drug prices and supporters of innovation like Ginn, who point out, “America didn’t become the world’s biotech leader through central planning. We got here when Washington, in a rare moment, actually loosened its regulatory grip.”

Ginn, who served as associate director for economic policy in the first Trump

See Full Page